Immunovant, Inc. (IMVT)

NASDAQ: IMVT · IEX Real-Time Price · USD
15.90
+0.19 (1.21%)
Mar 30, 2023, 11:01 AM EDT - Market open
1.21%
Market Cap 2.07B
Revenue (ttm) n/a
Net Income (ttm) -198.70M
Shares Out 130.25M
EPS (ttm) -1.66
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 204,207
Open 16.15
Previous Close 15.71
Day's Range 15.90 - 16.52
52-Week Range 3.15 - 20.24
Beta 1.05
Analysts Buy
Price Target 24.28 (+52.7%)
Earnings Date Feb 3, 2023

About IMVT

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquar... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Dr. Peter Salzmann M.B.A., M.D.
Employees 124
Stock Exchange NASDAQ
Ticker Symbol IMVT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 17 analysts, the average rating for IMVT stock is "Buy." The 12-month stock price forecast is $24.28, which is an increase of 52.70% from the latest price.

Price Target
$24.28
(52.70% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended December 31, 2022

NEW YORK, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today re...

1 month ago - GlobeNewsWire

4 Drug Stocks Up More Than 40% YTD With Room to Grow in 2023

Here are four drug companies, MRK, VRTX, IMCR and IMVT, that are up 40% or more in 2022 so far and still have room for growth in 2023.

Other symbols: IMCRMRKVRTX
3 months ago - Zacks Investment Research

Are Medical Stocks Lagging Immunovant (IMVT) This Year?

Here is how Immunovant, Inc. (IMVT) and McKesson (MCK) have performed compared to their sector so far this year.

3 months ago - Zacks Investment Research

Reasons to Add Immunovant (IMVT) Stock to Your Portfolio Now

Immunovant (IMVT) is progressing well with its lead pipeline candidate batoclimab being developed for treating myasthenia gravis, thyroid eye disease and other autoimmune diseases.

4 months ago - Zacks Investment Research

Immunovant (IMVT) Rises More Than 150% in 3 Months: Here's How

Immunovant (IMVT) is making good progress with its lead pipeline candidate, batoclimab, which is being developed for treating myasthenia gravis, thyroid eye disease and other autoimmune diseases.

4 months ago - Zacks Investment Research

Immunovant's (IMVT) Q2 Earnings In Line, Batoclimab in Focus

Immunovant's (IMVT) earnings meet estimates in the fiscal second quarter ending Sep 30, 2022. IMVT deepens focus on developing its lead candidate batoclimab.

5 months ago - Zacks Investment Research

Immunovant to Present at Guggenheim 4th Annual Immunology and Neurology Day on November 14th

NEW YORK, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today an...

5 months ago - GlobeNewsWire

Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended September 30, 2022

NEW YORK, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today re...

5 months ago - GlobeNewsWire

Immunovant (IMVT) Set to Develop Lead Candidate Batoclimab

Immunovant (IMVT) expects its lead pipeline candidate, batoclimab, being developed for treating several types of autoimmune diseases, to capture good market share, owing to its differentiated profile.

5 months ago - Zacks Investment Research

Immunovant Announces Pricing of $75.0 Million Underwritten Offering of Common Stock

NEW YORK, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today an...

6 months ago - GlobeNewsWire

Immunovant Announces IMVT-1402, a Next Generation Anti-FcRn

NEW YORK, Sept. 28, 2022 (GLOBE NEWSWIRE) --  Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today ...

6 months ago - GlobeNewsWire

Immunovant to Present at Roivant Investor Day on September 28th

NEW YORK, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today a...

6 months ago - GlobeNewsWire

Immunovant to Present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14th

NEW YORK, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today a...

7 months ago - GlobeNewsWire

UPDATE -- Immunovant Announces Two New Development Programs for Batoclimab

NEW YORK, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today ann...

7 months ago - GlobeNewsWire

Immunovant Announces Two New Development Programs for Batoclimab

NEW YORK, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today ann...

7 months ago - GlobeNewsWire

Immunovant (IMVT) Up More Than 20% in Past 3 Months: Here's Why

Immunovant's (IMVT) lead pipeline candidate, batoclimab, is being developed for treating myasthenia gravis, thyroid eye disease and other autoimmune diseases.

7 months ago - Zacks Investment Research

Immunovant, Inc. (IMVT) Upgraded to Buy: Here's Why

Immunovant, Inc. (IMVT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

7 months ago - Zacks Investment Research

Wall Street Analysts See an 114% Upside in Immunovant, Inc. (IMVT): Can the Stock Really Move This High?

The consensus price target hints at an 114.4% upside potential for Immunovant, Inc. (IMVT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earning...

7 months ago - Zacks Investment Research

Immunovant to Host Investor Webcast to Announce Two New Indications for Batoclimab on September 7, 2022

NEW YORK, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, will host ...

7 months ago - GlobeNewsWire

GSK NDA for Myelofibrosis Candidate Gets FDA Acceptance

GSK's NDA for momelotinib for treating myelofibrosis was based on data from key phase III studies, including the pivotal MOMENTUM study.

Other symbols: ALKSEDITGSK
8 months ago - Zacks Investment Research

Immunovant (IMVT) Focus on Developing Autoimmune Disease Drug

Immunovant (IMVT) remains focused on developing its lead pipeline candidate, batoclimab for treating several types of autoimmune diseases. The lack of other pipeline candidates remains a concern.

8 months ago - Zacks Investment Research

Wall Street Analysts Think Immunovant, Inc. (IMVT) Could Surge 142%: Read This Before Placing a Bet

The mean of analysts' price targets for Immunovant, Inc. (IMVT) points to a 142.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement amon...

8 months ago - Zacks Investment Research

Immunovant (IMVT) Loss Narrows in Q1, Focus on Batoclimab

Immunovant's (IMVT) earnings beat estimates in the fiscal first quarter ended on Jun 30, 2022. The company is evaluating batoclimab in a pivotal study for treating myasthenia gravis.

8 months ago - Zacks Investment Research

Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended June 30, 2022

NEW YORK, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today repo...

8 months ago - GlobeNewsWire

Why Is Immunovant, Inc. (IMVT) Up 13.9% Since Last Earnings Report?

Immunovant, Inc. (IMVT) reported earnings 30 days ago. What's next for the stock?

9 months ago - Zacks Investment Research